Study for GLP-1-based drugs on improving insulin sensitivity in newly diagnosis obese type 2 diabetic patients

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900020647

Enrollment

Unknown

Registered

2019-01-11

Start date

2019-01-01

Completion date

Unknown

Last updated

2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetes

Interventions

A:Liraglutide+Metformin

B:glimepiride+Metformin

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. type 2 diabetes newly diagnosed within 6-12 months; 2. aged 18-65 years; 3. No diabetic acute metabolic complications within 3 months; 4. 7.5% = HbA1c = 10.0%; 5. BMI 25-35kg/m2; 6. FPG:7~13.9mmol/L2hPG=11.1mmol/L; 7. TG=5mmol/L.

Exclusion criteria

Exclusion criteria: 1. Treatment with cholesterol-lowering drugs before recruitment; 2. Treatment with Exenatide, Liraglutide or other incretinergic regimen (before recruitment) except Metformin; 3. Severe renal, liver or heart disease; 4. Females of childbearing potential who are pregnant, breast-feeding, intend to become pregnant or are not using adequate contraceptive methods.

Design outcomes

Primary

Measure	Time frame
muscle microvascular blood flow;brachial flow mediated dilatation;HbA1c;	—

Secondary

Measure	Time frame
Liver function;Lipid levels;Body mass index;blood inflammatory markers;	—

Countries

China

Contacts

Public ContactShi Mengte

Department of Endocrinology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University

smt198853@163.com+86 13706673733

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026